.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Dow
McKinsey
Queensland Health
AstraZeneca
US Department of Justice
Cipla
US Army
Merck
Medtronic

Generated: July 23, 2017

DrugPatentWatch Database Preview

ALLI Drug Profile

« Back to Dashboard

What is the patent landscape for Alli, and when can generic versions of Alli launch?

Alli is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in thirty-three countries.

The generic ingredient in ALLI is orlistat. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the orlistat profile page.

Summary for Tradename: ALLI

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list58
Clinical Trials: see list10
Patent Applications: see list5,447
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ALLI at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons
ALLI
orlistat
CAPSULE;ORAL021887-001Feb 7, 2007OTCYesYes6,004,996► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALLI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons
ALLI
orlistat
CAPSULE;ORAL021887-001Feb 7, 20074,598,089► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ALLI

Drugname Dosage Strength RLD Submissiondate
orlistatCapsules60 mgAlli9/8/2010

International Patent Family for Tradename: ALLI

Country Document Number Estimated Expiration
Czech Republic287154► Subscribe
Malaysia118371► Subscribe
Australia713192► Subscribe
European Patent Office0921796► Subscribe
Cyprus2264► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALLI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0042Belgium► SubscribePRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
C/GB98/044United Kingdom► SubscribePRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
McKinsey
Fish and Richardson
Moodys
Cerilliant
Healthtrust
Merck
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot